HPV mRNA testing in cervical cancer screening: implications for low- and middle-income countries

Affiliations

¹ University of Miami Miller School of Medicine, Miami, Florida, USA.
² University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
³ Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, Philippine General Hospital, Manila, NCR, Philippines.
⁴ Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA deee1@mskcc.org.

^# Contributed equally.

Minh Ton et al. Int J Gynecol Cancer. 2022.

. 2022 Dec 5;32(12):1632-1633.

doi: 10.1136/ijgc-2022-003959.

¹ University of Miami Miller School of Medicine, Miami, Florida, USA.
² University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
³ Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, Philippine General Hospital, Manila, NCR, Philippines.
⁴ Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA deee1@mskcc.org.

^# Contributed equally.

No abstract available

Keywords: Cervical Cancer.

Conflict of interest statement

Competing interests: None declared.

1. Ferlay J, et al., Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer, 2015. 136(5): p. E359–86. - PubMed
1. Arbyn M, et al., Accuracy and effectiveness of HPV mRNA testing in cervical cancer screening: a systematic review and meta-analysis. Lancet Oncol, 2022. - PubMed
1. Catarino R, et al., Cervical cancer screening in developing countries at a crossroad: Emerging technologies and policy choices. World J Clin Oncol, 2015. 6(6): p. 281–90. - PMC - PubMed
1. Gen-Probe Incorporated., APTIMA® HPV Assay [package insert]. 2018: San Diego, CA, USA.
1. Curran GM, et al., Effectiveness-implementation hybrid designs: combining elements of clinical effectiveness and implementation research to enhance public health impact. Med Care, 2012. 50(3): p. 217–26. - PMC - PubMed